René Rückert

Arthur Andersen LLP used to provide accounting services. It was also into consulting services for clients that operate businesses throughout the United States and around the world. Arthur Andersen was founded in 1913 and was headquartered in Chicago, IL.

XL-protein GmbH is a German biopharmaceutical company that specializes in the development of long-acting immunosuppressive antibodies for the selective suppression of organ rejection. The private company is based in Freising, Germany and was founded by Claus Schalper, who has been the CEO since incorporation. The company collaborates with other research institutions to develop novel biopharmaceuticals with enhanced action, such as the genetic fusion or chemical coupling of biopharmaceuticals with fully biodegradable PAS sequences. XL-protein's PASylation® technology has demonstrated significantly extended systemic half-life in vivo, potentially offering improved treatment options for autoimmune diseases and cystic fibrosis.

Anavo Therapeutics BV is a Dutch company that specializes in developing first-in-class therapeutic programs for several indications in oncology. The company is based in Leiden, Netherlands. The company has attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. Anavo is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. Anavo is backed by blue-chip investors m ventures, inkef capital, taiho ventures, mrl ventures fund, and bioqube ventures. The company was founded by Claus Schalper, Birgit Zech, Gerhard Müller. Birgit Zech has been the CEO since incorporation.

Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland.

Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom.